The global market for Human Vaccines was estimated at US$46.9 Billion in 2024 and is projected to reach US$71.4 Billion by 2030, growing at a CAGR of 7.3% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions. The report includes the most recent global tariff developments and how they impact the Human Vaccines market.
Global Human Vaccines Market - Key Trends and Drivers Summarized
Unveiling the Power of Human Vaccines: A Cornerstone of Modern Medicine
Human vaccines stand as one of the greatest achievements in public health, offering protection against a myriad of infectious diseases by training the immune system to recognize and combat pathogens. Comprising antigens that mimic disease-causing organisms, vaccines are crucial in preparing the immune system to fight diseases quickly and effectively. This mechanism has successfully led to the eradication and reduction of numerous life-threatening diseases, such as smallpox and polio, significantly lowering morbidity and mortality worldwide. Vaccines not only safeguard individuals but also contribute to herd immunity, preventing the spread of infections across communities and thereby securing population health globally.
Navigating New Frontiers: Innovations Enhancing Vaccine Efficacy and Safety
The landscape of vaccine technology is constantly evolving, incorporating novel methods that promise greater protection and safety. Traditional vaccine strategies, while effective, are now being enhanced with cutting-edge approaches like mRNA vaccines and recombinant technologies. These innovations offer precise targeting and rapid scalability, particularly highlighted by their role in addressing global challenges such as the COVID-19 pandemic swiftly. Furthermore, the development of adjuvants and improved delivery systems continues to revolutionize vaccine efficacy, broadening the horizons for combating more complex diseases and tailoring immunizations to diverse populations.
Emerging Trends Reshaping the Global Vaccine Sector
Global demographic and technological trends are reshaping the vaccine industry. The increase in international travel and urbanization elevates the risk of infectious disease transmission, amplifying the need for effective vaccination programs. Simultaneously, rising health consciousness and improved healthcare infrastructure are driving up vaccine uptake globally, especially in regions previously underserved. Technological advancements such as digital immunization tracking and AI in healthcare are also enhancing the reach and efficiency of vaccination campaigns, ensuring wider and more effective coverage.
What Drives the Growth in the Human Vaccines Market?
The growth in the human vaccines market is driven by several factors, including the increasing prevalence of infectious diseases, rising global health awareness, and advancements in vaccine research and development. Enhanced funding and investments by governments and global health organizations to eliminate infectious diseases contribute significantly to the expansion and innovation within the vaccine sector. The COVID-19 pandemic has particularly highlighted the critical role of vaccines in global health security, leading to unprecedented public and private partnerships focused on vaccine development and distribution. Moreover, demographic factors such as aging populations and the rise in chronic health conditions that increase susceptibility to infections necessitate continued vaccine development and uptake. Together, these dynamics underscore the vital role of vaccines in contemporary medicine and public health, ensuring ongoing investment and research in this essential field.
Key Insights:
Market Growth: Understand the significant growth trajectory of the Intramuscular & Subcutaneous segment, which is expected to reach US$58.7 Billion by 2030 with a CAGR of a 7.8%. The Oral segment is also set to grow at 5.3% CAGR over the analysis period.
Regional Analysis: Gain insights into the U.S. market, valued at $12.4 Billion in 2024, and China, forecasted to grow at an impressive 11.7% CAGR to reach $16.8 Billion by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.
Why You Should Buy This Report:
Detailed Market Analysis: Access a thorough analysis of the Global Human Vaccines Market, covering all major geographic regions and market segments.
Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Human Vaccines Market.
Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.
Key Questions Answered:
How is the Global Human Vaccines Market expected to evolve by 2030?
What are the main drivers and restraints affecting the market?
Which market segments will grow the most over the forecast period?
How will market shares for different regions and segments change by 2030?
Who are the leading players in the market, and what are their prospects?
Report Features:
Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2024 to 2030.
In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
Company Profiles: Coverage of players such as ALK - Abelló A/S, Altimmune, Inc., Astellas Pharma Inc., Bavarian Nordic A/S, Bharat Biotech and more.
Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.
Some of the 16 companies featured in this Human Vaccines market report include:
ALK - Abelló A/S
Altimmune, Inc.
Astellas Pharma Inc.
Bavarian Nordic A/S
Bharat Biotech
BiondVax Pharmaceuticals Ltd.
GlaxoSmithKline Plc
Hualan Biological Engineering Inc.
Janssen Pharmaceuticals Inc.
MedImmune
Mitsubishi Tanabe Pharma
Pfizer Inc.
Sanofi Pasteur SA
Seqirus
Serum Institute of India Pvt. Ltd.
SK BioScience
Takeda Pharmaceutical Company Limited
Zydus Cadila
This edition integrates the latest global trade and economic shifts as of June 2025 into comprehensive market analysis. Key updates include:
Tariff and Trade Impact: Insights into global tariff negotiations across 180+ countries, with analysis of supply chain turbulence, sourcing disruptions, and geographic realignment. Special focus on 2025 as a pivotal year for trade tensions, including updated perspectives on the Trump-era tariffs.
Adjusted Forecasts and Analytics: Revised global and regional market forecasts through 2030, incorporating tariff effects, economic uncertainty, and structural changes in globalization. Includes segmentation by product, technology, type, material, distribution channel, application, and end-use, with historical analysis since 2015.
Strategic Market Dynamics: Evaluation of revised market prospects, regional outlooks, and key economic indicators such as population and urbanization trends.
Innovation & Technology Trends: Latest developments in product and process innovation, emerging technologies, and key industry drivers shaping the competitive landscape.
Competitive Intelligence: Updated global market share estimates for 2025, competitive positioning of major players (Strong/Active/Niche/Trivial), and refined focus on leading global brands and core players.
Expert Insight & Commentary: Strategic analysis from economists, trade experts, and domain specialists to contextualize market shifts and identify emerging opportunities.
Complimentary Update: Buyers receive a free July 2025 update with finalized tariff impacts, new trade agreement effects, revised projections, and expanded country-level coverage.
Table of Contents
I. METHODOLOGYII. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
Influencer Market Insights
Tariff Impact on Global Supply Chain Patterns
Global Economic Update
Human Vaccines - Global Key Competitors Percentage Market Share in 2024 (E)
Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
Advances in Genetic and Recombinant Technology Expands Vaccine Efficacy
Demand Grows for Pediatric and Adult Vaccines Globally
Rising Awareness and Education About Vaccine Preventable Diseases
Integration of AI and Machine Learning in Vaccine Development
Innovations in Vaccine Delivery Systems and Adjuvants
Vaccination Programs on Public Health Systems Spur Vaccines Usage & Penetration Among Susceptible Populations
Emergence of New Pathogens Drives Demand for Novel Vaccines
Vaccine to Prevent HIV Still in the Pipeline
R&D Interest in Personalized Cancer Vaccines Gains Momentum
4. GLOBAL MARKET PERSPECTIVE
Table 1: World Human Vaccines Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
Table 2: World Recent Past, Current & Future Analysis for Human Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
Table 3: World Historic Review for Human Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
Table 4: World 15-Year Perspective for Human Vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
Table 5: World Recent Past, Current & Future Analysis for Intramuscular & Subcutaneous by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
Table 6: World Historic Review for Intramuscular & Subcutaneous by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
Table 7: World 15-Year Perspective for Intramuscular & Subcutaneous by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
Table 8: World Recent Past, Current & Future Analysis for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
Table 9: World Historic Review for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
Table 10: World 15-Year Perspective for Oral by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
Table 11: World Recent Past, Current & Future Analysis for Other Administration Routes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
Table 12: World Historic Review for Other Administration Routes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
Table 13: World 15-Year Perspective for Other Administration Routes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
Table 14: World Recent Past, Current & Future Analysis for Conjugate by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
Table 15: World Historic Review for Conjugate by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
Table 16: World 15-Year Perspective for Conjugate by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
Table 17: World Recent Past, Current & Future Analysis for Recombinant by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
Table 18: World Historic Review for Recombinant by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
Table 19: World 15-Year Perspective for Recombinant by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
Table 20: World Recent Past, Current & Future Analysis for Inactivated & Subunit by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
Table 21: World Historic Review for Inactivated & Subunit by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
Table 22: World 15-Year Perspective for Inactivated & Subunit by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
Table 23: World Recent Past, Current & Future Analysis for Live Attenuated by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
Table 24: World Historic Review for Live Attenuated by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
Table 25: World 15-Year Perspective for Live Attenuated by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
Table 26: World Recent Past, Current & Future Analysis for Other Technologies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
Table 27: World Historic Review for Other Technologies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
Table 28: World 15-Year Perspective for Other Technologies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
III. MARKET ANALYSIS
UNITED STATES
Human Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
Table 29: USA Recent Past, Current & Future Analysis for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
Table 30: USA Historic Review for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
Table 31: USA 15-Year Perspective for Human Vaccines by Administration Route - Percentage Breakdown of Value Sales for Intramuscular & Subcutaneous, Oral and Other Administration Routes for the Years 2015, 2025 & 2030
Table 32: USA Recent Past, Current & Future Analysis for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
Table 33: USA Historic Review for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
Table 34: USA 15-Year Perspective for Human Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies for the Years 2015, 2025 & 2030
CANADA
Table 35: Canada Recent Past, Current & Future Analysis for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
Table 36: Canada Historic Review for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
Table 37: Canada 15-Year Perspective for Human Vaccines by Administration Route - Percentage Breakdown of Value Sales for Intramuscular & Subcutaneous, Oral and Other Administration Routes for the Years 2015, 2025 & 2030
Table 38: Canada Recent Past, Current & Future Analysis for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
Table 39: Canada Historic Review for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
Table 40: Canada 15-Year Perspective for Human Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies for the Years 2015, 2025 & 2030
JAPAN
Human Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
Table 41: Japan Recent Past, Current & Future Analysis for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
Table 42: Japan Historic Review for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
Table 43: Japan 15-Year Perspective for Human Vaccines by Administration Route - Percentage Breakdown of Value Sales for Intramuscular & Subcutaneous, Oral and Other Administration Routes for the Years 2015, 2025 & 2030
Table 44: Japan Recent Past, Current & Future Analysis for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
Table 45: Japan Historic Review for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
Table 46: Japan 15-Year Perspective for Human Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies for the Years 2015, 2025 & 2030
CHINA
Human Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
Table 47: China Recent Past, Current & Future Analysis for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
Table 48: China Historic Review for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
Table 49: China 15-Year Perspective for Human Vaccines by Administration Route - Percentage Breakdown of Value Sales for Intramuscular & Subcutaneous, Oral and Other Administration Routes for the Years 2015, 2025 & 2030
Table 50: China Recent Past, Current & Future Analysis for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
Table 51: China Historic Review for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
Table 52: China 15-Year Perspective for Human Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies for the Years 2015, 2025 & 2030
EUROPE
Human Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
Table 53: Europe Recent Past, Current & Future Analysis for Human Vaccines by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
Table 54: Europe Historic Review for Human Vaccines by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
Table 55: Europe 15-Year Perspective for Human Vaccines by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
Table 56: Europe Recent Past, Current & Future Analysis for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
Table 57: Europe Historic Review for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
Table 58: Europe 15-Year Perspective for Human Vaccines by Administration Route - Percentage Breakdown of Value Sales for Intramuscular & Subcutaneous, Oral and Other Administration Routes for the Years 2015, 2025 & 2030
Table 59: Europe Recent Past, Current & Future Analysis for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
Table 60: Europe Historic Review for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
Table 61: Europe 15-Year Perspective for Human Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies for the Years 2015, 2025 & 2030
FRANCE
Human Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
Table 62: France Recent Past, Current & Future Analysis for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
Table 63: France Historic Review for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
Table 64: France 15-Year Perspective for Human Vaccines by Administration Route - Percentage Breakdown of Value Sales for Intramuscular & Subcutaneous, Oral and Other Administration Routes for the Years 2015, 2025 & 2030
Table 65: France Recent Past, Current & Future Analysis for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
Table 66: France Historic Review for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
Table 67: France 15-Year Perspective for Human Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies for the Years 2015, 2025 & 2030
GERMANY
Human Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
Table 68: Germany Recent Past, Current & Future Analysis for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
Table 69: Germany Historic Review for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
Table 70: Germany 15-Year Perspective for Human Vaccines by Administration Route - Percentage Breakdown of Value Sales for Intramuscular & Subcutaneous, Oral and Other Administration Routes for the Years 2015, 2025 & 2030
Table 71: Germany Recent Past, Current & Future Analysis for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
Table 72: Germany Historic Review for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
Table 73: Germany 15-Year Perspective for Human Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies for the Years 2015, 2025 & 2030
ITALY
Table 74: Italy Recent Past, Current & Future Analysis for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
Table 75: Italy Historic Review for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
Table 76: Italy 15-Year Perspective for Human Vaccines by Administration Route - Percentage Breakdown of Value Sales for Intramuscular & Subcutaneous, Oral and Other Administration Routes for the Years 2015, 2025 & 2030
Table 77: Italy Recent Past, Current & Future Analysis for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
Table 78: Italy Historic Review for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
Table 79: Italy 15-Year Perspective for Human Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies for the Years 2015, 2025 & 2030
UNITED KINGDOM
Human Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
Table 80: UK Recent Past, Current & Future Analysis for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
Table 81: UK Historic Review for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
Table 82: UK 15-Year Perspective for Human Vaccines by Administration Route - Percentage Breakdown of Value Sales for Intramuscular & Subcutaneous, Oral and Other Administration Routes for the Years 2015, 2025 & 2030
Table 83: UK Recent Past, Current & Future Analysis for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
Table 84: UK Historic Review for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
Table 85: UK 15-Year Perspective for Human Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies for the Years 2015, 2025 & 2030
SPAIN
Table 86: Spain Recent Past, Current & Future Analysis for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
Table 87: Spain Historic Review for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
Table 88: Spain 15-Year Perspective for Human Vaccines by Administration Route - Percentage Breakdown of Value Sales for Intramuscular & Subcutaneous, Oral and Other Administration Routes for the Years 2015, 2025 & 2030
Table 89: Spain Recent Past, Current & Future Analysis for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
Table 90: Spain Historic Review for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
Table 91: Spain 15-Year Perspective for Human Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies for the Years 2015, 2025 & 2030
RUSSIA
Table 92: Russia Recent Past, Current & Future Analysis for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
Table 93: Russia Historic Review for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
Table 94: Russia 15-Year Perspective for Human Vaccines by Administration Route - Percentage Breakdown of Value Sales for Intramuscular & Subcutaneous, Oral and Other Administration Routes for the Years 2015, 2025 & 2030
Table 95: Russia Recent Past, Current & Future Analysis for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
Table 96: Russia Historic Review for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
Table 97: Russia 15-Year Perspective for Human Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies for the Years 2015, 2025 & 2030
REST OF EUROPE
Table 98: Rest of Europe Recent Past, Current & Future Analysis for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
Table 99: Rest of Europe Historic Review for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
Table 100: Rest of Europe 15-Year Perspective for Human Vaccines by Administration Route - Percentage Breakdown of Value Sales for Intramuscular & Subcutaneous, Oral and Other Administration Routes for the Years 2015, 2025 & 2030
Table 101: Rest of Europe Recent Past, Current & Future Analysis for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
Table 102: Rest of Europe Historic Review for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
Table 103: Rest of Europe 15-Year Perspective for Human Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies for the Years 2015, 2025 & 2030
ASIA-PACIFIC
Human Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
Table 104: Asia-Pacific Recent Past, Current & Future Analysis for Human Vaccines by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
Table 105: Asia-Pacific Historic Review for Human Vaccines by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
Table 106: Asia-Pacific 15-Year Perspective for Human Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
Table 107: Asia-Pacific Recent Past, Current & Future Analysis for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
Table 108: Asia-Pacific Historic Review for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
Table 109: Asia-Pacific 15-Year Perspective for Human Vaccines by Administration Route - Percentage Breakdown of Value Sales for Intramuscular & Subcutaneous, Oral and Other Administration Routes for the Years 2015, 2025 & 2030
Table 110: Asia-Pacific Recent Past, Current & Future Analysis for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
Table 111: Asia-Pacific Historic Review for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
Table 112: Asia-Pacific 15-Year Perspective for Human Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies for the Years 2015, 2025 & 2030
AUSTRALIA
Human Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
INDIA
Human Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
SOUTH KOREAREST OF ASIA-PACIFIC
LATIN AMERICA
Human Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
ARGENTINABRAZILMEXICOREST OF LATIN AMERICA
MIDDLE EAST
Human Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
IRANISRAELSAUDI ARABIAUNITED ARAB EMIRATESREST OF MIDDLE EAST
AFRICA
Human Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
IV. COMPETITION
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
The Human Vaccine market is a segment of the larger Vaccine industry, which focuses on the development and distribution of vaccines to protect humans from infectious diseases. Vaccines are typically administered through injections, although some may be administered orally or nasally. Vaccines are designed to stimulate the body's immune system to recognize and fight off a particular disease. Vaccines are typically developed through a combination of laboratory research, clinical trials, and regulatory approval.
The Human Vaccine market is highly competitive, with a number of large pharmaceutical companies and biotechnology firms competing for market share. Companies in the market are focused on developing new vaccines, as well as improving existing vaccines. They are also involved in the production, distribution, and marketing of vaccines.
Some of the major companies in the Human Vaccine market include Merck & Co., GlaxoSmithKline, Pfizer, Sanofi, Johnson & Johnson, and Novartis. Show Less Read more
This product is a market research report. Each license type allows a set number of users to access the report. Please select an option from the list below. This product is a market research report. This is a single user license, allowing one user access to the product. The product is a PDF. This product is a market research report. This is a 1-10 user license, allowing up to ten users have access to the product. The product is a PDF. This product is a market research report. This is an enterprise license, allowing all employees within your organization access to the product. The product is a PDF.